Codexis Inc. [CDXS] Is Currently -44.74 below its 200 Period Moving Avg: What Does This Mean?

Related

Codexis Inc. [NASDAQ: CDXS] closed the trading session at $6.67 on 07/15/22. The day’s price range saw the stock hit a low of $6.15, while the highest price level was $8.51. The company report on July 14, 2022 that Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets).


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient (API) in PAXLOVID™, Pfizer’s antiviral therapeutic, which is currently authorized for emergency use by the U.S. Food and Drug Administration (“FDA”) for the treatment of mild-to-moderate COVID-19 in people at high risk of progression to severe illness and authorized or approved by other regulatory authorities across the globe.

“Pfizer has played a critical role in the response to the global COVID-19 pandemic, including through their rapid development of PAXLOVID™, and I am incredibly proud that Codexis’ engineered enzyme is enabling a sustainable manufacturing route for their nirmatrelvir API,” said John Nicols, President and CEO of Codexis. “This agreement demonstrates the agility of Codexis’ commercial supply chain and manufacturing capabilities to very rapidly generate unprecedented enzyme quantities. We look forward to our continued support of Pfizer’s manufacturing of PAXLOVID™ for COVID-19 patients.”.

The stocks have a year to date performance of -78.67 percent and weekly performance of -47.06 percent. The stock has been moved at -73.69 percent over the last six months. The stock has performed -24.80 percent around the most recent 30 days and changed -65.22 percent over the most recent 3-months.

If compared to the average trading volume of 878.19K shares, CDXS reached to a volume of 13173961 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Codexis Inc. [CDXS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CDXS shares is $24.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CDXS stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Codexis Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 31, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on March 02, 2022, representing the official price target for Codexis Inc. stock. Previously, the target price had yet another raise to $32, while Piper Sandler analysts kept a Overweight rating on CDXS stock.

The Average True Range (ATR) for Codexis Inc. is set at 1.16, with the Price to Sales ratio for CDXS stock in the period of the last 12 months amounting to 6.46. The Price to Book ratio for the last quarter was 2.73.

CDXS stock trade performance evaluation

Codexis Inc. [CDXS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -47.06. With this latest performance, CDXS shares dropped by -24.80% in over the last four-week period, additionally sinking by -73.69% over the last 6 months – not to mention a drop of -66.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CDXS stock in for the last two-week period is set at 29.71, with the RSI for the last a single of trading hit 23.15, and the three-weeks RSI is set at 33.42 for Codexis Inc. [CDXS]. The present Moving Average for the last 50 days of trading for this stock 10.52, while it was recorded at 11.11 for the last single week of trading, and 21.64 for the last 200 days.

Codexis Inc. [CDXS]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Codexis Inc. [CDXS] shares currently have an operating margin of -21.67 and a Gross Margin at +75.83. Codexis Inc.’s Net Margin is presently recorded at -20.31.

Return on Equity for this stock declined to -12.72, with Return on Assets sitting at -9.09.

Codexis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 4.90.

Earnings per share (EPS) analysis for Codexis Inc. [CDXS] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CDXS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Codexis Inc. go to 15.00%.

Codexis Inc. [CDXS]: Insider Ownership positions

There are presently around $422 million, or 99.90% of CDXS stock, in the hands of institutional investors. The top three institutional holders of CDXS stocks are: BAILLIE GIFFORD & CO with ownership of 7,386,628, which is approximately 2.843% of the company’s market cap and around 2.30% of the total institutional ownership; BLACKROCK INC., holding 5,183,443 shares of the stock with an approximate value of $34.57 million in CDXS stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $29.93 million in CDXS stock with ownership of nearly 13.796% of the company’s market capitalization.

Positions in Codexis Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 84 institutional holders increased their position in Codexis Inc. [NASDAQ:CDXS] by around 5,482,015 shares. Additionally, 85 investors decreased positions by around 10,228,135 shares, while 27 investors held positions by with 47,608,474 shares. The mentioned changes placed institutional holdings at 63,318,624 shares, according to the latest SEC report filing. CDXS stock had 16 new institutional investments in for a total of 274,565 shares, while 36 institutional investors sold positions of 1,106,098 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]